证券代码：301047 证券简称：义翘神州 公告编号：2023-048 北京义翘神州科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开第二届董事会第五次会议，审议通过了《关于提请召开 2023 年第二次临 时股东大会的议案》。根据《中华人民共和国公司法》（以下简称"《公司法》"） 和《北京义翘神州科技股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，公司拟于 2023 年 9 月 13 日（星期三）召开 2023 年第二次临时股东大 会，现将会议有关事项通知如下： 一、会议召开的基本情况 （一）会议届次：2023 年第二次临时股东大会 （二）会议召集人：公司董事会 （三）会议召开的合法性及合规性：本次股东大会的召开符合有关法律、法 规、规范性文件和《公司章程》的相关规定。 （四）会议召开时间： 1、会议召开时间：2023 年 9 月 13 日（星期三）下午 14:30 2、网络投票时间：2023 年 9 ...

证券代码：301047 证券简称：义翘神州 公告编号：2023-049 特此公告。 北京义翘神州科技股份有限公司监事会 2023 年 8 月 28 日 1 附件：王晓彤先生简历 北京义翘神州科技股份有限公司 关于监事辞职暨补选监事的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）监事会近日收到监事 隋英男先生的书面辞职报告，隋英男先生因工作安排申请辞去其所担任的公司第 二届监事会非职工代表监事职务。隋英男先生辞职后将不担任公司任何职务。 隋英男先生的辞职将导致公司监事会成员低于法定最低人数，根据《中华人 民共和国公司法》《北京义翘神州科技股份有限公司章程》（以下简称"《公司 章程》"）的规定，其辞职申请将自公司股东大会选举产生新任监事后生效，在 此期间隋英男先生将继续履行其监事职责。 隋英男先生原定任期至 2026 年 3 月 22 日。截至本公告日，隋英男先生未持 有公司股份，不存在应当履行而未履行的承诺。隋英男先生在担任公司监事期间 勤勉尽责，监事会对隋英男先生任职期间为公司所作的贡献表示衷心的感谢。 ...

北京义翘神州科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日 召开第二届董事会第五次会议和第二届监事会第五次会议，审议通过了《关于使 用部分闲置自有资金进行现金管理的议案》，同意公司使用额度不超过人民币 400,000.00 万元的闲置自有资金进行现金管理，有效期自公司股东大会审议通过 之日起 12 个月内有效。该议案尚需提交公司股东大会审议批准。现将具体情况 公告如下： 一、本次使用部分自有资金进行现金管理的情况 1、现金管理目的 为提高资金使用效率，在不影响公司正常经营的情况下，合理利用公司部分 自有资金进行现金管理，增加公司收益，实现收益最大化。 2、现金管理产品品种 证券代码：301047 证券简称：义翘神州 公告编号：2023-045 公司将按照相关规定严格控制风险，对现金管理产品进行严格评估，购买投资 期限不超过 12 个月的银行或其他金融机构发行的安全性高、流动性好的中低风 险产品，包括但不限于结构性存款 ...

证券代码：301047 证券简称：义翘神州 公告编号：2023-041 北京义翘神州科技股份有限公司 第二届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京义翘神州科技股份有限公司（以下简称"公司"）第二届董事会第五次 会议于 2023 年 8 月 25 日在公司会议室以现场与通讯方式召开，本次会议的通知 于 2023 年 8 月 15 日以通讯方式送达全体董事。本次会议应出席董事 9 人，实际 出席董事 9 人，公司监事及高级管理人员列席了本次会议。本次会议由董事长谢 良志博士主持，会议的召集和召开程序符合《中华人民共和国公司法》《北京义 翘神州科技股份有限公司章程》的有关规定。 二、董事会会议审议情况 经与会董事充分讨论，会议以投票表决方式审议通过了如下议案： 1、审议通过《关于公司<2023 年半年度报告及其摘要>的议案》 公司 2023 年半年度报告全文及摘要包含的信息公允、全面、真实地反映了 本报告期的财务状况和经营成果等事项，所披露的信息真实、准确、完整，不存 在任何虚假记载、误导性陈述或重大遗 ...

证券代码：301047 证券简称：义翘神州 公告编号：2023-046 北京义翘神州科技股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开第二届董事会第五次会议和第二届监事会第五次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司使用额度不超过人民币 200,000.00 万元的暂时闲置募集资金（含超募资金）进行现金管理，有效期自公 司股东大会审议通过之日起 12 个月内有效。该议案尚需提交公司股东大会审议。 现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 7 月 13 日出具的《关于同意北京义翘神州科技股份有限公司首次公开发行股票注册 的批复》（证监许可〔2021〕2364 号），公司首次公开发行人民币普通股（A 股）1,700 万股，每股面值 1 元，每股发行价为人民币 292.92 元，募集资金总额 为人民币 4,979,6 ...

根据中国证券监督管理委员会（以下简称"中国证监会"）于 2021 年 7 月 13 日出具的《关于同意北京义翘神州科技股份有限公司首次公开发行股票注册 的批复》（证监许可〔2021〕2364 号），公司首次公开发行人民币普通股（A 股）1,700 万股，每股面值 1 元，每股发行价为人民币 292.92 元，募集资金总额 为人民币 4,979,640,000.00 元，扣除发行费用（不含税）人民币 255,885,733.88 元，募集资金净额为人民币 4,723,754,266.12 元，其中超募资金为人民币 3,823,754,266.12 元。上述募集资金已全部到位，经致同会计师事务所（特殊普 通合伙）审验并于 2021 年 8 月 9 日出具了致同验字（2021）第 110C000555 号 《验资报告》。公司设立了募集资金专项账户，并与相关银行及保荐机构中信证 券股份有限公司分别签订了《募集资金三方监管协议》《募集资金四方监管协议》， 对募集资金的存放和使用进行专户管理。 二、募集资金投资项目情况 证券代码：301047 证券简称：义翘神州 公告编号：2023-047 北京义翘神州科技股份有限公司 ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：2023-002 | --- | --- | --- | |--------------------|---------------|-------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 | √业绩说明会 | | 投资者关系活动类别 | | | | | □新闻发布会 | □路演活动 | □现场参观 √其他（电话会议、论坛） 王凯旋、韩世通、王郑洋 中信证券股份有限公司； YangHuangCreditSuisse、赵悦伦 瑞信证券（中国）有限 公司；胡亚新 永赢基金管理有限公司；魏巍 中信期货 有限公司；秦墅隆 国新证券股份有限公司；张树声 益 民基金管理有限公司；王海华 银河基金管理有限公司； 王琦、梅寒青、赵海春 国金证券股份有限公司；Lizheng Zhu 富达基金（香港）有限公司；杨芳 国盛证券有限责 任公司；张熙 野村东方国际证券有限公司；马千里 国 信证券股份有限公司；陈智博 首创证券股份有限公司； 参与单位名称 姚书远 中国银河证券股份有限公司；凌静怡 ...

股票代码：301047 证券简称：义翘神州 北京义翘神州科技股份有限公司 投资者关系活动记录表 编号：2023-001 | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | --- | --- | | 投资者关系活动类别 | | | | □新闻发布会 □路演活动 | | | □现场参观 □其他（电话会议、论坛） | | 参与单位名称 | 投资者网上提问 | | 时间 | 年 月 日 (周五) 下午 2023 4 28 15:00-17:00 | | 地点 | 公 司 通 过 全 景 网 投 资 者 关 系 互 动 平 台 " " | | | （https://ir.p5w.net）采用网络远程的方式召开业绩说明会 | | | 董事、总经理、研发总监 张杰 | | 上市公司接待人员 | 董事、财务总监、董事会秘书 冯涛 | | | 独立董事 尹师州 | | | 保荐代表人 赵陆胤 | | | Q1、50 亿理财资金如何用好？ | | | 回复：尊敬的投资者您好，关于资金使用，一方面公司 | | | 将充分保证研发投入及市场拓展需要，支撑公司核心主 | | | 业发展；另一方面，公司也正在积极寻 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥157,085,973.09, a decrease of 10.67% compared to ¥175,846,115.52 in the same period last year[4] - Net profit attributable to shareholders was ¥83,695,323.17, down 26.74% from ¥114,247,512.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥49,977,078.41, reflecting a decline of 46.73% from ¥93,809,708.75 in the previous year[4] - Basic earnings per share decreased by 61.44% to ¥0.6478 from ¥1.6801 in the previous year[4] - Total operating revenue for Q1 2023 was ¥157,085,973.09, a decrease of 10.7% from ¥175,846,115.52 in the same period last year[41] - Net profit for Q1 2023 was ¥83,695,323.17, down 26.8% from ¥114,247,512.43 in Q1 2022[42] - Basic earnings per share for Q1 2023 were ¥0.6478, compared to ¥1.6801 in the same period last year[43] - The total comprehensive income for Q1 2023 was ¥81,548,148.47, compared to ¥113,288,428.01 in Q1 2022[43] Cash Flow - The net cash flow from operating activities was ¥33,235,082.48, a significant drop of 51.92% compared to ¥69,121,768.37 in the same quarter last year[4] - The net cash flow from operating activities decreased by 51.92% to ¥33,235,082.48 compared to ¥69,121,768.37 in the previous year, primarily due to increased payments for employee salaries and goods[31] - The net cash flow from investing activities dropped significantly by 114.50% to -¥85,192,213.86 from ¥587,466,728.92 in the previous year, mainly due to cash management and fixed asset purchases[31] - The net cash flow from financing activities improved by 99.20% to -¥5,442,871.92 compared to -¥682,728,089.17 in the previous year, mainly due to cash dividends paid in the previous period[31] - The net cash flow from investing activities was CNY -85.192 million, compared to CNY 587.467 million in the previous year[45] - The net cash flow from financing activities was CNY -5.443 million, compared to CNY -682.728 million in the previous year[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,645,508,110.09, an increase of 1.14% from ¥6,570,390,331.09 at the end of the previous year[4] - The total liabilities amounted to ¥193,877,170.53, a decrease from ¥201,007,464.00 in the previous period[20] - The total assets were reported at ¥6,645,508,110.09, slightly down from ¥6,570,390,331.09 in the previous year[20] - The total equity attributable to shareholders increased to ¥6,451,630,939.56 from ¥6,369,382,867.09 in the previous year[20] - The total current assets were reported at ¥6,023,974,157.98, slightly up from ¥5,922,136,726.91 in the previous year[20] - The company’s long-term investments in equity instruments amounted to ¥186,239,867.00, reflecting a stable investment strategy[20] Research and Development - Research and development expenses increased by 113.30% to ¥23,668,344.76, primarily due to the expansion of the R&D team[13] - Research and development expenses for Q1 2023 were ¥23,668,344.76, significantly higher than ¥11,096,271.31 in Q1 2022, indicating increased investment in innovation[41] Government Support and Other Income - The company received government subsidies amounting to ¥2,256,178.76, which included talent project subsidies and other government support[10] - The company reported a significant increase in other income, which rose by 577.28% to ¥2,588,821.76, mainly due to increased government subsidies[13] Market and Business Strategy - The company is exploring market expansion strategies, although specific details were not disclosed in the financial report[39] - The report indicates a focus on regular business growth despite a decline in overall revenue[47] Dividend Distribution - The company plans to distribute a cash dividend of ¥25,840,000 (including tax), amounting to ¥20.00 per 10 shares, pending shareholder approval[37] Miscellaneous - The company has not undergone an audit for the Q1 2023 report[56] - The cash flow from operating activities was not detailed in the provided content but is critical for assessing overall performance[45] - The company experienced a foreign exchange impact of CNY -2.393 million on cash and cash equivalents[45] - Cash and cash equivalents at the end of the period were CNY 2.289 billion, down from CNY 2.837 billion at the end of the previous year[45]

Product Development and Offerings - In 2022, the company launched approximately 1,000 new products, maintaining a core position as a major supplier of infectious disease research reagents with around 68,000 stock products by the end of the year[2]. - The company has developed a product line that includes thousands of biological reagent products, catering to diverse customer research needs[89]. - The company has developed a product library with over 6,500 protein reagent products and approximately 14,000 antibody reagent products, along with around 47,000 gene products[169]. - The company’s recombinant proteins include over 4,500 human cell-expressed products, meeting customer demands for proteins that closely resemble natural human structures and properties[129]. - The company emphasizes the importance of customized services in the biological reagent market, which is expanding due to increasing personalized demands[68]. Financial Performance - The company's operating revenue for 2022 was ¥574,603,390.32, a decrease of 40.47% compared to ¥965,272,540.65 in 2021[56]. - The net profit attributable to shareholders for 2022 was ¥303,134,958.32, down 57.90% from ¥720,013,671.11 in 2021[56]. - The net profit after deducting non-recurring gains and losses was ¥244,352,925.89, a decline of 59.04% compared to ¥596,583,791.15 in the previous year[56]. - The basic earnings per share for 2022 was ¥2.6614, representing a 79.05% decrease from ¥12.7061 in 2021[56]. - The total assets at the end of 2022 were ¥6,570,390,331.09, a decrease of 4.64% from ¥6,890,235,257.55 at the end of 2021[56]. Market Expansion and Strategy - The company signed a lease with Haines Company in November 2022 to establish a new bioresearch center in Houston, Texas, marking a significant step in its global strategic layout[5]. - The company has established subsidiaries in the US, Europe, and Japan, enhancing local service support capabilities[91]. - The company plans to enhance its market position through mergers and acquisitions to increase market concentration in the biological reagent industry[69]. - The company is focused on expanding its market presence through local teams and subsidiaries in key regions[91]. - The company has expanded its market presence in developed countries, establishing subsidiaries in the US, Germany, and Japan to enhance its global footprint[146]. Research and Development - The company plans to continue enhancing its R&D capabilities and expanding its market presence to ensure long-term sustainable development[4]. - The company has a strong R&D team with 44 PhDs, a 19% increase from the previous year, and over 25% of employees holding master's degrees or higher[146]. - The company's overall R&D investment increased by 49.88% year-on-year, enhancing its core competitiveness[168]. - The company emphasizes strong R&D capabilities and rapid response to market demands, exemplified by completing related protein development in just 6 days during the COVID-19 crisis[115]. - The company aims to leverage AI technology and automation in laboratory research to support new product development and enhance its competitive capabilities[186]. Customer Base and Market Demand - The top five customers accounted for CNY 106.94 million in sales, representing 18.61% of the total annual sales, with the largest customer contributing 7.48%[12]. - The company supports over 7,000 clients globally, including universities, research institutions, and pharmaceutical R&D companies, enhancing its brand reputation in the biological reagent industry[103]. - The demand for customized products and services has increased, prompting the company to strengthen local logistics and customer service teams[90]. - The bioreagent and technical service market is characterized by diverse customer needs and a lack of unified quality standards, which the company aims to address[89]. - The company is actively expanding its service business and improving customer satisfaction, leading to a continuous increase in market share and revenue growth[4]. Operational Challenges and Adjustments - The company's unconventional business related to COVID-19 saw a significant decline of 73.19% year-on-year, prompting a strategic business adjustment[187]. - The fourth quarter net profit was significantly impacted by fluctuations in the financial market, particularly due to changes in the fair value of financial products[59]. - Direct labor costs increased by 66.20% to ¥38,390,531.54, making up 44.62% of total operating costs[194]. - Material costs rose by 16.78% to ¥28,843,653.21, accounting for 33.52% of total operating costs[194]. - The company has established a strict quality assessment and control standard for its biological reagent products, ensuring compliance with various operational procedures[135]. Government Support and Subsidies - The company reported government subsidies of CNY 14.78 million in 2022, a decrease from CNY 67.11 million in 2021[22]. - The company has achieved ISO9001, ISO13485, and CNAS certifications, and its purification workshop has passed GMP compliance certification[191]. - The company has established a comprehensive quality management system certified by ISO9001, ISO13485, and CNAS, ensuring product quality throughout its lifecycle[158].